Published in J Clin Oncol on February 01, 1986
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents. J Clin Invest (1987) 1.26
Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor. J Exp Med (1989) 1.14
Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia (2010) 1.09
Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors. J Clin Invest (1990) 1.07
Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function. Prostaglandins Other Lipid Mediat (2011) 0.89
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective. J Interferon Cytokine Res (2013) 0.89
Gamma interferon treatment in vivo provokes accumulation of activated monocytes in the venous circulation of rats. Am J Pathol (1990) 0.88
Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity. Infect Immun (1989) 0.88
Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg (2000) 0.83
Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer (2015) 0.82
High-dose interferon-gamma alters the distribution of B lymphocytes and macrophages in rat spleen and lymph nodes. Immunology (1993) 0.81
Interferon for treatment: the dust settles. Br Med J (Clin Res Ed) (1988) 0.80
The role of interferons in the treatment of malignant neoplasms. Yale J Biol Med (1989) 0.75
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol (1988) 14.21
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Secretory products of macrophages. J Clin Invest (1987) 10.33
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med (1989) 7.72
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res (1991) 6.99
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering. J Exp Med (1977) 5.44
Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med (1979) 5.38
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med (1976) 5.05
Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature (1977) 4.75
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest (1981) 4.46
Ly antigens as markers for functionally distinct subpopulations of thymus-derived lymphocytes of the mouse. Nature (1975) 4.34
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med (1986) 4.05
Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A (1991) 4.01
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol (1985) 3.85
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med (1979) 3.61
Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1966) 3.56
Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol (1990) 3.55
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J (1991) 3.41
Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem (1989) 3.31
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med (1989) 2.99
Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med (1993) 2.98
A simple method for counting adherent cells: application to cultured human monocytes, macrophages and multinucleated giant cells. J Immunol Methods (1983) 2.75
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med (1978) 2.69
Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1989) 2.59
Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J (1991) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med (1999) 2.51
A semi-automated micro-assay for H2O2 release by human blood monocytes and mouse peritoneal macrophages. J Immunol Methods (1985) 2.46
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41
N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem (1991) 2.38
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest (1982) 2.23
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci U S A (1981) 2.09
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Mechanisms of macrophage antimicrobial activity. Trans R Soc Trop Med Hyg (1983) 2.01
Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res (1984) 1.98
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A (1988) 1.97
Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med (1998) 1.96
Ly phenotype of cytotoxic T cells for syngeneic tumor. J Exp Med (1976) 1.94
Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science (1990) 1.91
Rescue of endogenous 30S retroviral sequences from mouse cells by baboon type C virus. J Virol (1978) 1.90
Inhibition of leukemias in man by L-asparaginase. Cancer Res (1967) 1.88
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol (1997) 1.87
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med (1982) 1.85
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res (1999) 1.85
Trace levels of bacterial lipopolysaccharide prevent interferon-gamma or tumor necrosis factor-alpha from enhancing mouse peritoneal macrophage respiratory burst capacity. J Immunol (1987) 1.85
Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J Natl Cancer Inst (1968) 1.84
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med (1991) 1.83
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Secretion of oxygen intermediates: role in effector functions of activated macrophages. Fed Proc (1982) 1.81
Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages. J Exp Med (1975) 1.77
Characterization of the nonphagocytic adherent cell from the peritoneal cavity of normal and BCG-treated mice. J Immunol (1977) 1.77
Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest (1990) 1.74
Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J Exp Med (1998) 1.74
Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res (1987) 1.74
Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. Curr Opin Microbiol (2000) 1.73
Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med (1981) 1.71
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
L-citrulline production from L-arginine by macrophage nitric oxide synthase. The ureido oxygen derives from dioxygen. J Biol Chem (1990) 1.70
Serologic approaches to the study of cancer in animals and in man. Cancer Res (1968) 1.65
Decreased phagocytosis by peritoneal macrophages from BCG-treated mice: induction of the phagocytic defect in normal macrophages with BCG in vitro. Cell Immunol (1977) 1.61
Secretion of pyruvate. An antioxidant defense of mammalian cells. J Exp Med (1987) 1.61
Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest (1988) 1.59
FAD and GSH participate in macrophage synthesis of nitric oxide. Biochem Biophys Res Commun (1990) 1.59
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA (1982) 1.58
Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med (1982) 1.58
Enzymatic basis of macrophage activation. Kinetic analysis of superoxide production in lysates of resident and activated mouse peritoneal macrophages and granulocytes. J Biol Chem (1984) 1.54
Synthesis of nitrogen oxides from L-arginine by macrophage cytosol: requirement for inducible and constitutive components. Biochem Biophys Res Commun (1989) 1.53
Induction and immunological properties of tumor necrosis factor. J Reticuloendothel Soc (1978) 1.53
Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. Cancer Res (1975) 1.51
Ly antigens: markers of T cell function on mouse spleen cells. J Immunol (1975) 1.49
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg (1987) 1.44